AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23161001 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (all doses)
Number of subjects: 10
Study 21692277 — intervention group
Group type: EXPERIMENTAL
Intervention: Chonggu (EX‐HN 27) deep insertion group
Number of subjects: 283
Study 21692277 — intervention group
Group type: EXPERIMENTAL
Intervention: Chonggu (EX‐HN 27) shallow insertion group
Number of subjects: 283
Study 21692277 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture group
Number of subjects: 283
Study 19238452 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (5 mg for children ≤30 kg, 10 mg for children >30 kg, doubled for two additional months)
Number of subjects: 25
Study 19238452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 16918945 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid plus mineralocorticoid hormone replacement
Number of subjects: 5
Study 16918945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 15190719 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital clock for temporal information
Number of subjects: 0
Study 15190719 — intervention group
Group type: EXPERIMENTAL
Intervention: Overflow tank for spatial information
Number of subjects: 0
Study 15190719 — intervention group
Group type: COMPARATOR
Intervention: Static displays
Number of subjects: 0
Study 15190719 — intervention group
Group type: COMPARATOR
Intervention: Animated displays
Number of subjects: 0
Study 10911825 — intervention group
Group type: EXPERIMENTAL
Intervention: Stinging nettle leaf (Urtica dioica) applied daily for one week
Number of subjects: 27
Study 10911825 — intervention group
Group type: COMPARATOR
Intervention: Placebo, white deadnettle leaf (Lamium album)
Number of subjects: 27
Study 9304948 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiring Psychological Nursing
Number of subjects: 176
Study 9304948 — intervention group
Group type: COMPARATOR
Intervention: General medical care (Control)
Number of subjects: 176
Study 8375461 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal respiratory rate
Number of subjects: 9
Study 8375461 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% slower respiratory rate
Number of subjects: 9
Study 8375461 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% faster respiratory rate
Number of subjects: 9
Study 3535980 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation training (ART) taught during one session using participant demonstration, written instructions, taped instructions, or a combination of all three; practice at home encouraged.
Number of subjects: 0
Study 3535980 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 0
Study 3535980 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation training (ART)
Number of subjects: 0
Study 30394148 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone plus phototherapy
Number of subjects: 60
Study 30394148 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus phototherapy
Number of subjects: 60
Study 30394148 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 28295581 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus (initial dose: 0.2 mg/kg/day)
Number of subjects: 25
Study 28295581 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release tacrolimus (initial dose: 0.1 mg/kg/day)
Number of subjects: 25
Study 28295581 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus
Number of subjects: 25
Study 28295581 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release tacrolimus
Number of subjects: 25
Study 26610843 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental vibrational force (AcceleDent) 20-minutes/day
Number of subjects: 81
Study 26610843 — intervention group
Group type: COMPARATOR
Intervention: Non-functional (sham) device
Number of subjects: 81
Study 26610843 — intervention group
Group type: COMPARATOR
Intervention: Fixed-appliances only
Number of subjects: 81
Study 23569311 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg with docetaxel 100 mg/m(2) and trastuzumab 8 mg/kg loading dose followed by 6 mg/kg, administered every 3 weeks
Number of subjects: 424
Study 23569311 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 100 mg/m(2) and trastuzumab 8 mg/kg loading dose followed by 6 mg/kg without bevacizumab, administered every 3 weeks
Number of subjects: 424
Study 23569311 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg with docetaxel and trastuzumab
Number of subjects: 424
Study 23569311 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel and trastuzumab without bevacizumab
Number of subjects: 424
Study 23569311 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing therapy
Number of subjects: 424
Study 21483158 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 40
Study 21483158 — intervention group
Group type: COMPARATOR
Intervention: 10 mg atorvastatin
Number of subjects: 40
Study 19500335 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (anti-TNF therapy)
Number of subjects: 0
Study 19500335 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study 19500335 — intervention group
Group type: EXPERIMENTAL
Intervention: RA patients
Number of subjects: 0
Study 17031005 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Frequency Questionnaire (FFQ)
Number of subjects: 399
Study 17031005 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Day Food Records (4DFR)
Number of subjects: 399
Study 17031005 — intervention group
Group type: COMPARATOR
Intervention: Demographic and behavioral factors (smoking, gender, education)
Number of subjects: 399
Study 14699862 — intervention group
Group type: EXPERIMENTAL
Intervention: L dose group (8 mumol Fe/kg)
Number of subjects: 84
Study 14699862 — intervention group
Group type: EXPERIMENTAL
Intervention: H dose group (12 mumol Fe/kg)
Number of subjects: 84
Study 10820297 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude upper cervical adjustment
Number of subjects: 36
Study 10820297 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (control)
Number of subjects: 36
Study 8893144 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitriol (0.25 microgram/day)
Number of subjects: 25
Study 8893144 — intervention group
Group type: COMPARATOR
Intervention: Uraemic patients
Number of subjects: 25
Study 1709686 — intervention group
Group type: COMPARATOR
Intervention: Pelvic radiotherapy (RT; arm A)
Number of subjects: 107
Study 1709686 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by pelvic radiotherapy (CT + RT; arm B) - three cycles of chemotherapy (BOMP: bleomycin, vincristine, mitomycin, and cisplatin) followed by RT
Number of subjects: 107
Study 6402369 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral MESNA (840 mg/m2 at 0 hr, 4 hr, and 8 hr p.i.)
Number of subjects: 45
Study 6402369 — intervention group
Group type: COMPARATOR
Intervention: Conventional prophylactic measures (raised fluid intake and forced diuresis)
Number of subjects: 45
Study 31682230 — intervention group
Group type: EXPERIMENTAL
Intervention: HVTT-PVTT score (differentiating < 3 and ≥ 3 points)
Number of subjects: 869
Study 31682230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression model and CART algorithm
Number of subjects: 869
Study 28535076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cingal (4 mL, 88 mg hyaluronic acid plus 18 mg triamcinolone hexacetonide)
Number of subjects: 368
Study 28535076 — intervention group
Group type: COMPARATOR
Intervention: Monovisc (4 mL, 88 mg hyaluronic acid)
Number of subjects: 368
Study 28535076 — intervention group
Group type: COMPARATOR
Intervention: Saline (4 mL, 0.9%)
Number of subjects: 368
Study 26862988 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 45
Study 26862988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 24804695 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (intramuscular testosterone undecanoate for 40 weeks)
Number of subjects: 88
Study 23122652 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg per day (IV)
Number of subjects: 581
Study 23122652 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta 1a 44 μg (SC)
Number of subjects: 581
Study 23122652 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 581
Study 23122652 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta 1a
Number of subjects: 581
Study 20573586 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT) in CP+NGT group
Number of subjects: 32
Study 20573586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Glucose Tolerance Test (IVGTT) in CP+NGT group
Number of subjects: 32
Study 20573586 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT) in CP+IGT group
Number of subjects: 32
Study 20573586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Glucose Tolerance Test (IVGTT) in CP+IGT group
Number of subjects: 32
Study 20573586 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT) in CP+DM group
Number of subjects: 32
Study 20573586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Glucose Tolerance Test (IVGTT) in CP+DM group
Number of subjects: 32
Study 20573586 — intervention group
Group type: COMPARATOR
Intervention: Oral Glucose Tolerance Test (OGTT) in healthy subjects
Number of subjects: 32
Study 20573586 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Glucose Tolerance Test (IVGTT) in healthy subjects
Number of subjects: 32
Study 18075302 — intervention group
Group type: EXPERIMENTAL
Intervention: PDGF BB
Number of subjects: 0
Study 18075302 — intervention group
Group type: COMPARATOR
Intervention: Imatinib mesylate (Gleevec)
Number of subjects: 0
Study 18075302 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant ascites
Number of subjects: 0
Study 15625138 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral furosemide daily for 5 days with oral potassium supplementation
Number of subjects: 264
Study 15625138 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 264
Study 12163426 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg/d
Number of subjects: 332
Study 12163426 — intervention group
Group type: COMPARATOR
Intervention: amlodipine 5 mg/d
Number of subjects: 332
Study 10492056 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin in patients with renal dysfunction
Number of subjects: 0
Study 10492056 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 0
Study 10492056 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with alpha1‐AGP levels over 0.9 mg/ml
Number of subjects: 0
Study 10492056 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with alpha1‐AGP levels less than 0.7 mg/ml
Number of subjects: 0
Study 10492056 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 0
Study 8942423 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C and E (1 g ascorbic acid and 400 mg dl-alpha-tocopheryl acetate)
Number of subjects: 20
Study 8942423 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (400 mg dl-alpha-tocopheryl acetate)
Number of subjects: 20
Study 8942423 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (1 g ascorbic acid)
Number of subjects: 20
Study 8942423 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C and E
Number of subjects: 20
Study 2048459 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training
Number of subjects: 52
Study 2048459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral mood management training
Number of subjects: 52
Study 6763373 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline sulphate (250, 500, or 1000 micrograms)
Number of subjects: 10
Study 6763373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31322601 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless-steel pediatric crowns (SCC)
Number of subjects: 68
Study 31322601 — intervention group
Group type: COMPARATOR
Intervention: Compomer filling
Number of subjects: 68
Study 31322601 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC
Number of subjects: 68
Study 29242039 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinse A (1.5% KOX, pH 4.5)
Number of subjects: 0
Study 29242039 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinse B (1.5% KOX, pH 7.0)
Number of subjects: 0
Study 29242039 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinse C (2.0% KOX, 45 ppm fluoride, pH 4.5)
Number of subjects: 0
Study 29242039 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse (no KOX or fluoride, pH 4.5)
Number of subjects: 0
Study 26635263 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring (n=30)
Number of subjects: 82
Study 26635263 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital monitoring (n=52)
Number of subjects: 82
Study 24521353 — intervention group
Group type: EXPERIMENTAL
Intervention: WPC-RUTF
Number of subjects: 0
Study 24521353 — intervention group
Group type: COMPARATOR
Intervention: P-RUTF
Number of subjects: 0
Study 23118720 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% FFA suppositories
Number of subjects: 30
Study 23118720 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 30
Study 19440265 — intervention group
Group type: EXPERIMENTAL
Intervention: PUP law enforcement and reducing minors' access to commercial sources of tobacco
Number of subjects: 24
Study 19440265 — intervention group
Group type: COMPARATOR
Intervention: Reducing minors' access to commercial sources of tobacco
Number of subjects: 24
Study 17878744 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of alprazolam orally
Number of subjects: 24
Study 14716761 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine at 1250 mg/m² twice daily on Days 2-15 and irinotecan at 300 mg/m² on Day 1 (Arm A)
Number of subjects: 140
Study 14716761 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine at 1250 mg/m² twice daily on Days 2-15 and irinotecan at 150 mg/m² on Days 1 and 8 (Arm B)
Number of subjects: 140
Study 14716761 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of capecitabine (1000 mg/m²) and irinotecan (Arm A: 240 mg/m²; Arm B: 120 mg/m²)
Number of subjects: 140
Study 11124289 — intervention group
Group type: EXPERIMENTAL
Intervention: Emedastine 0.05%
Number of subjects: 97
Study 11124289 — intervention group
Group type: COMPARATOR
Intervention: Levocabastine 0.05%
Number of subjects: 97
Study 9282256 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric balanced diet (HCBD)
Number of subjects: 55
Study 9282256 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein sparing modified fast diet (PSMF)
Number of subjects: 55
Study 7950459 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 HRZ2 6 HR2 (experimental group)
Number of subjects: 0
Study 7950459 — intervention group
Group type: COMPARATOR
Intervention: 3 HR/3 HR2/6 H2 (control group)
Number of subjects: 0
Study 3514082 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg daily, with option to reduce to 10 mg at week 4 or 8)
Number of subjects: 2035
Study 3514082 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (750 mg daily, with option to reduce to 500 mg at week 4 or 8)
Number of subjects: 2035
Study 3345774 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (doses of 20, 30, 40, 50, 60, 80 and 100% of the maximum tolerable dose)
Number of subjects: 6
Study 3345774 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid (concentrations of 1‐100 mM)
Number of subjects: 6
Study 30387374 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Power (CP) derived from self-paced time-trial prediction trials
Number of subjects: 12
Study 30387374 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Threshold Power (FTP)
Number of subjects: 12
Study 28195948 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril plus acetyl salicylic acid
Number of subjects: 265
Study 28195948 — intervention group
Group type: COMPARATOR
Intervention: Ramipril plus acetyl salicylic acid
Number of subjects: 265
Study 28195948 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril
Number of subjects: 265
Study 28195948 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 265
Study 25180525 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 657
Study 25180525 — intervention group
Group type: COMPARATOR
Intervention: White girls
Number of subjects: 657
Study 23343329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-phone based assessment via text-messages or Android application
Number of subjects: 24
Study 23343329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-phone based assessment
Number of subjects: 24
Study 21973110 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured 10-session psychosocial support group intervention
Number of subjects: 361
Study 18535768 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality measures based on CONSORT statement and additional check items
Number of subjects: 13
Study 17071213 — intervention group
Group type: EXPERIMENTAL
Intervention: Group behavior therapy (BT)
Number of subjects: 24
Study 17071213 — intervention group
Group type: COMPARATOR
Intervention: Group supportive therapy (ST)
Number of subjects: 24
Study 17071213 — intervention group
Group type: COMPARATOR
Intervention: Naturalistic waiting period
Number of subjects: 24
Study 12576845 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol sclerotherapy
Number of subjects: 67
Study 12576845 — intervention group
Group type: COMPARATOR
Intervention: Hydrocelectomy
Number of subjects: 67
Study 12576845 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 67
Study 11093990 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal clinical care algorithm (Group I)
Number of subjects: 139
Study 11093990 — intervention group
Group type: COMPARATOR
Intervention: Standard balanced outpatient anesthetic with ondansetron 4 mg (Group II)
Number of subjects: 139
Study 11093990 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group III)
Number of subjects: 139
Study 9373420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy and maintenance cognitive therapy
Number of subjects: 75
Study 9373420 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants and maintenance antidepressants
Number of subjects: 75
Study 9373420 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants and maintenance cognitive therapy
Number of subjects: 75
Study 1616387 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding
Number of subjects: 98
Study 1616387 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (C)
Number of subjects: 98
Study 3987804 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated pellets of erythromycin base administered 1 hour before breakfast
Number of subjects: 24
Study 3987804 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated tablets
Number of subjects: 24
Study 3987804 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated pellets of erythromycin base during a non-standardized breakfast
Number of subjects: 24
Study 29770553 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional help sheet
Number of subjects: 101
Study 29770553 — intervention group
Group type: COMPARATOR
Intervention: Implementation intention
Number of subjects: 101
Study 27759625 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin (320 mg single dose) plus amoxicillin (1g twice daily), bismuth (240 mg), and omeprazole (20 mg) for 14 days
Number of subjects: 120
Study 27759625 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin-containing therapy
Number of subjects: 120
Study 24188146 — intervention group
Group type: EXPERIMENTAL
Intervention: Acculturation measures in English
Number of subjects: 574
Study 24188146 — intervention group
Group type: EXPERIMENTAL
Intervention: Acculturation measures in Spanish
Number of subjects: 574
Study 24188146 — intervention group
Group type: COMPARATOR
Intervention: Acculturation measures (both languages)
Number of subjects: 574
Study 21949432 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low‐pressure pulsatile lavage treatment with 1 L of normal saline at 11 psi of pressure
Number of subjects: 28
Study 21949432 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 28
Study 20470671 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg in combination with concurrent radiotherapy (RT) +/‐ concomitant cisplatin
Number of subjects: 15
Study 20470671 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib and RT with concurrent cisplatin
Number of subjects: 15
Study 20470671 — intervention group
Group type: COMPARATOR
Intervention: Baseline S‐VEGF levels
Number of subjects: 15
Study 17868194 — intervention group
Group type: EXPERIMENTAL
Intervention: +TRP
Number of subjects: 16
Study 17868194 — intervention group
Group type: COMPARATOR
Intervention: -TRP
Number of subjects: 16
Study 15998268 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic debridement (Fm-UD)
Number of subjects: 41
Study 15998268 — intervention group
Group type: COMPARATOR
Intervention: Quadrant scaling/root planing (Q-SRP)
Number of subjects: 41
Study 15998268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic re-treatment
Number of subjects: 41
Study 15998268 — intervention group
Group type: COMPARATOR
Intervention: Hand instrumentation re-treatment
Number of subjects: 41
Study 12921607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary treatment of chronic gastritis (plan A)
Number of subjects: 214
Study 12921607 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional dyspepsia treatment (plan B)
Number of subjects: 214
Study 11094001 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline (HS)
Number of subjects: 40
Study 11094001 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 40
Study 9010701 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (20 or 30 mg)
Number of subjects: 28
Study 9010701 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (75 or 100 mg)
Number of subjects: 28